Virtual Library
Start Your Search
H.F. Dinçbaş
Author of
-
+
P1.07 - Poster Session with Presenters Present (ID 459)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.07-043 - Patterns of Failure and the Prognostic Factors of the Patients with LD SCLC according to the TNM Staging; TOG-TROD Study (ID 6100)
14:30 - 14:30 | Author(s): H.F. Dinçbaş
- Abstract
Background:
The prognostic factors and patterns of relapse were retrospectively analyzed according to the TNM staging in Turkish patients with limited SCLC on behalf of Turkish Oncology Group(TOG)-Turkish Radiation Oncology Association(TROD).
Methods:
The data of 266 patients with limited disease SCLC from 13 multiple oncology centers who have at least 1 year follow-up were analyzed. The patients were restaged according to TNM staging by means of their initial thorax-CT or PET-CT . Brain MRI was performed for all of the patients before treatment. Median age was 59(21-86) years old and 85% of the patients were male. PET-CT was used in 62.4 % of the patients for staging. Concomitant chemoradiotherapy with Cisplatinum-Etoposide was given in 38.3% of the patients. Median thoracic radiotherapy dose was 56Gy(30-66.8Gy). PCI was performed to the 180 patients (67.7%) , The effect of age, gender,clinical stage, T, N stage and prophylactic cranial irradiation(PCI) on OS and DFS rates were analyzed in both univariate and multivariate analysis with Log-rank and cox regression tests.
Results:
Median follow-up was 19 months(6-113 ) for the patients who are alive. Thirty-six percent of the patients had LR and approximately half of the patients developed DM. The most common metastases were seen in brain, liver and bone respectively. 2 and 5 years OS and DFS were 45.3%-20.6% and 32.2%-17.1% retrospectively. On univariate analysis, OS was significantly better in the patients with T1, N0-1 tumors and clinical stage I-II than the others and patients who did not developed brain and DM and thoracic radiotherapy dose >60Gy(p<0.05). DFS was superior in patients with N0-1 tumor, stage I-II disease, who received PCI and thoracic radiotherapy dose >60Gy(p<0.05). On multivariate analysis, PCI was found to be an independent factor affecting DFS (p=0.042). DM, thoracic radiotherapy dose were significant prognostic factors for OS (p=0.048, <0.0001 respectively). 64 patients developed brain metastases with a median 16 months(6-113months). Brain metastases were find to be significantly less in the patients with N0 , stage I-II disease and who were treated by PCI.
Conclusion:
Limited disease definition includes wide spectrum of patients, therefore TNM staging should be useful in order to predict the prognosis of the patients. In our series, DFS and OS was superior for the patients with T1 and N0-NI tumors than the others . Besides, the patients with T1 and N0 tumors developed fewer brain metastases, therefore PCI might be omitted for some of the patients with early staged tumor.
-
+
P2.02 - Poster Session with Presenters Present (ID 462)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Locally Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.02-041 - The Impact of Surgical Resection after Concurrent Chemotherapy and High Dose (61 Gy) Radiation in Stage IIIA/N2 Non-Small Cell Lung Cancer (ID 6304)
14:30 - 14:30 | Author(s): H.F. Dinçbaş
- Abstract
Background:
Locally advanced stage IIIA non-small-cell lung cancer with N2 disease is the most advanced stage at which cure can be achieved, but more than 60% of patients eventually die from their disease. For patients with stage IIIA/N2 disease, two standard treatment options are offered: definitive concurrent chemoradiotherapy or surgery combined with chemo/radiotherapy. We aimed to investigate the role of surgery after concurrent chemoterapy and high dose radiation in patients with N2 disease.
Methods:
Between January 2011 and December 2015 eligible patients had pathologically proven, stage IIIA/N2 non-small-cell lung cancer and were prospectively recorded. Those in the chemoradiotherapy group received three cycles of neoadjuvant chemotherapy (AUCx2 carpoplatin and docetaxel 85 mg/m[2 ] docetaxel) and concurrent radiotherapy with 61.2 Gy in 34 fractions over 3 weeks followed by surgical resection, and those in the control group received definitive chemoradiotherapy alone. All patients in two groups were proven to have no N2 disease after chemoradiotherapy.
Results:
A total of 58 patients were enrolled, of whom 21 received chemoradiotherapy followed by surgical resection and 37 had chemoradiotherapy only. Median overall survival was 35 months (95% CI 10.5–44.0) in the chemoradiotherapy + surgery group and 20.3 months (4.5–38.6) in the chemotherapy group (p=0.03). Median overall survival was 37·1 months (95% CI 22·6–50·0) with radiotherapy, compared with 26·2 months (19·9–52·1) in the control group. One patients died in the surgery group within 30 days after surgery.
Conclusion:
Pulmonary resection after high-dose neoadjuvant chemoradiotherapy is safe and surgical resection after chemoradiotherapy may provide better survival in histologically proven N2 stage IIIA non-small cell lung cancer.
